MEDICINE DETAILS
Roactemra
Active ingredient: Tocilizumab
Neutral reference profile for an independent medicine-access consultancy enquiry about Roactemra (Tocilizumab). No medicine is offered for sale.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Roactemra used for?
RoActemra (tocilizumab) is a medication indicated for the treatment of:
- Adults with severe rheumatoid arthritis that is worsening in patients who have not been previously treated with a medicine called methotrexate.
- Adults with moderate to severe active rheumatoid arthritis whose previous treatments with disease-modifying antirheumatic drugs (DMARDs), such as methotrexate or medicines known as tumor necrosis factor (TNF) blockers, have not worked well or were not tolerated.
- Children from 1 year of age with active systemic juvenile idiopathic arthritis in whom other treatments (with anti-inflammatory medicines called NSAIDs and corticosteroids) have not worked well enough.
- Children from 2 years of age with juvenile idiopathic polyarthritis in whom treatment with methotrexate has not worked well enough.
- COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.
It is used in combination with methotrexate for these conditions but can be used on its own in patients in whom methotrexate did not work well enough.
It is available in vial form for injection, each containing 20 mg/ml 400 mg of tocilizumab.
It is approved by the Food and Drug Administration (FDA), USA, under the brand name Actemra.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Roactemra identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
20 mg/ml (80 mg total) · 1 vial Catalogue organisation: Roche Pharma AG
-
20 mg/ml (80 mg total) · 4 vials Catalogue organisation: Roche Pharma AG
-
20 mg/ml (200 mg total) · 1 vial Catalogue organisation: Roche Pharma AG
-
20 mg/ml (200 mg total) · 4 vials Catalogue organisation: Roche Pharma AG
-
20 mg/ml (400 mg total) · 4 vials Catalogue organisation: Roche Pharma AG
-
20 mg/ml (400 mg total) concentrate for solution for infusion · 1 vial Catalogue organisation: CC Pharma GmbH
-
162 mg solution for injection · 4 pens Catalogue organisation: kohlpharma GmbH
-
162 mg solution for injection · 4 pre-filled syringes Catalogue organisation: kohlpharma GmbH
-
162 mg solution for injection · 12 pens Catalogue organisation: PARANOVA PACK A/S
-
162 mg solution for injection · 12 pre-filled syringes Catalogue organisation: CC Pharma GmbH
OFFICIAL SOURCES
Check the Roactemra record at an official source.
Search for “Roactemra” or “Tocilizumab”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Roactemra.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Roactemra
01What is Roactemra?＋
This directory record associates the brand name Roactemra with the active ingredient Tocilizumab. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Roactemra strengths and packs are recorded?＋
The catalogue currently shows: 20 mg/ml (80 mg total) · 1 vial; 20 mg/ml (80 mg total) · 4 vials; 20 mg/ml (200 mg total) · 1 vial; 20 mg/ml (200 mg total) · 4 vials. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Roactemra?＋
Catalogue records currently name: Roche Pharma AG, CC Pharma GmbH, kohlpharma GmbH. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Roactemra?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Roactemra, payment request, stock guarantee or binding offer.
06Can I buy Roactemra from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.